Details of the Drug Combinations

General Information of This Drug (ID: DMOU173)

Drug Name

CP-945598 DMOU173

Synonyms

Otenabant; Otenabant hydrochloride; CP 945598; Otenabant hydrochloride (USAN); CP-945,598; Otenabant (USAN/INN); 1-(8-(2-Chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide monohydrochloride; 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)purin-6-yl]-4-ethylamino-piperidine-4-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Obesity	5B81	Discontinued in Phase 3	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
CP-945598 + Ruxolitinib	DCZYEGX	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[2]
------------------------------------------------------------------------------------

References

1	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
2	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.